Hoth Therapeutics, Inc. (NASDAQ:HOTH) traded at $1.53 at last check on Monday, May 03, made an upward move of 1.39% on its previous day’s price.
Looking at the stock we see that its previous close was $1.51 and the beta (5Y monthly) reads 0 with the day’s price range being $1.4800 – 1.7500. The company has a trailing 12-month PE ratio of 0. In terms of its 52-week price range, HOTH has a high of $4.96 and a low of $1.4. The company’s stock has gained about -23.35% over that past 30 days.
Hoth Therapeutics, Inc. has a market cap of $34.01 Million and is expected to release its quarterly earnings report in June. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the HOTH stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.09, with the EPS growth for the year raised at -$0.38 for 2021 and -$0.43 for next year. These figures represent -0.34% and 0.13% growth in EPS for the two years respectively.
On the other hand, looking at the outlook for the HOTH stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Based on estimates by 1 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Hoth Therapeutics, Inc. (HOTH) stock as a Hold, while 1 rate it as a Buy. None analyst(s) rate it as outperform while none of them rated it as underperform, whereas none suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the HOTH stock currently stands at 0, and the most recent price level today is -7.66% off its SMA20 and -21.92% from its 50-day simple moving average. The RSI (14) is pointing at 37.44 while the volatility over the past week is 4.14% and jumps to 7.98% over the past one month. The beta value is 0, while the average true range (ATR) is currently pointing at 0.15. The average price target for the stock over the next 12 months is $10, with the estimates having a low of $10 and a high of $10. These price ends are 553.59% and +553.59% off the today’s price level respectively, although investors could be excited at the prospect of a +553.59% if the HOTH share price touches on the median price of $10.
Let’s briefly compare Hoth Therapeutics, Inc. (HOTH) stock to its peers. We find that today’s price change of +1.39% and -57.46% over the past 12 months for HOTH competes that of Bristol-Myers Squibb Company (BMY), which has seen its stock price rise 1.43% in the latest trading session and is +2.65% over the last one year. Another of its peers Amgen Inc (AMGN) has climbed 1.7% today, and was +0.18% up over the past year, while Gilead Sciences Inc (GILD) is also up 1.39% yet, while its price remains in the red at -57.46% over the same period. Hoth Therapeutics, Inc. has a P/E ratio of 0 compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 19.85. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.36% and 0.83%, respectively, in early deals.
Coming back to Hoth Therapeutics, Inc. (NASDAQ:HOTH), we note that the average 3-month trading volume was 3.82 Million, while that of the preceding 10-day period stands at 757.67 Million. Current shares outstanding are 22.83 Million.
According to data from Thomson Reuters, insiders hold 27.54% of the company’s shares while institutions hold 5.18%. The data shows that short shares as of April 14, 2021, stood at 896.08 Million at a short ratio of 0.18. This represents a 3.93% short interest in shares outstanding on April 14, 2021. Shares short rose in April from the previous month at 1.11 Million. Investors should be worried about this stock as its upside potential is weak, with today’s price pushing the stock -36.29% down in year-to-date price movement.